{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:47:12Z","timestamp":1777416432726,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.mayocp.2016.09.015","type":"journal-article","created":{"date-parts":[[2016,11,19]],"date-time":"2016-11-19T10:00:20Z","timestamp":1479549620000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer"],"prefix":"10.1016","volume":"92","author":[{"given":"James S.","family":"Goodwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Baillargeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.mayocp.2016.09.015_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.015_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1185\/03007995.2015.1016605","article-title":"Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy","volume":"31","author":"Modi","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mayocp.2016.09.015_bib3","unstructured":"The American Society for Bone and Mineral Research, the National Osteoporosis Foundation and the National Bone Health Alliance. Statement: nation's scientific and medical bone health experts call for action on dangers of not treating osteoporosis more aggressively. http:\/\/www.asbmr.org\/About\/PressReleases\/Detail.aspx?cid=e22b66f7-337a-46f7-93cc-f6b29479b9e1. Accessed June 21,\u00a02016."},{"issue":"10","key":"10.1016\/j.mayocp.2016.09.015_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.mayocp.2016.09.015_bib5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2016.09.015_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2474-15-112","article-title":"Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries","volume":"15","author":"Yun","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.015_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.015_bib8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.2565","article-title":"Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis","volume":"30","author":"Jha","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mayocp.2016.09.015_bib9","unstructured":"Kolata G. Fearing drugs' rare side effects, millions take their chances with osteoporosis. The New York Times. June 1, 2016. http:\/\/www.nytimes.com\/2016\/06\/02\/health\/osteoporosis-drugs-bones.html. Accessed June 21,\u00a02016."},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.015_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jbmr.233","article-title":"Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007","volume":"26","author":"Wang","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.mayocp.2016.09.015_bib11","unstructured":"Kolata G. Drug for bones is newly linked to jaw disease. The New York Times. June 2, 2006. http:\/\/www.nytimes.com\/2006\/06\/02\/health\/02jaw.html. Accessed June 21,\u00a02016."},{"key":"10.1016\/j.mayocp.2016.09.015_bib12","unstructured":"Parker-Pope T. New cautions about long-term use of bone drugs. The New York Times. May 9, 2012. http:\/\/well.blogs.nytimes.com\/2012\/05\/09. Accessed June 21,\u00a02016."},{"key":"10.1016\/j.mayocp.2016.09.015_bib13","unstructured":"Singer N. High stakes for Merck in litigation on fosamax. The New York Times. September 2, 2009. http:\/\/www.nytimes.com\/2009\/09\/03\/business\/03drug.html. Accessed June 21,\u00a02016."},{"issue":"10","key":"10.1016\/j.mayocp.2016.09.015_bib14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"13","key":"10.1016\/j.mayocp.2016.09.015_bib15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jnci\/djm025","article-title":"Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis","volume":"99","author":"Wilkinson","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.015_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older","volume":"58","author":"Boonen","year":"2010","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"10","key":"10.1016\/j.mayocp.2016.09.015_bib17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1345\/aph.1Q239","article-title":"Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates","volume":"45","author":"Baillargeon","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"18","key":"10.1016\/j.mayocp.2016.09.015_bib18","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.015_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaw in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.mayocp.2016.09.015_bib20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3899\/jrheum.100221","article-title":"Bisphosphonate associated osteonecrosis of the jaw","volume":"38","author":"Kahn","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.015_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.015_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.015_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.015_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37664","article-title":"Evaluation of an algorithm ascertaining cases or osteonecrosis of the jaw in the Swedish National Patient Register","volume":"5","author":"Bergdahl","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.015_bib25","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/ar2731","article-title":"Can health care databases be used to identify incident cases of osteonecrosis?","volume":"11","author":"Vlad","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.015_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.canep.2012.03.012","article-title":"Positive predictive value of the International Classification of Diseases, 10th revision, codes to identify osteonecrosis of the jaw in patients with cancer","volume":"36","author":"Gammelager","year":"2012","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.015_bib27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.joms.2006.02.011","article-title":"Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it Osteonecrosis?","volume":"64","author":"Zavras","year":"2006","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.015_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11926-011-0168-8","article-title":"Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies","volume":"13","author":"Zhang","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.015_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/pds.3292","article-title":"Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis","volume":"21","author":"Tennis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.015_bib30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/jop.12031","article-title":"Laboratory methods and biomarkers in the evaluation of bisphosphonate effects on body tissues: a literature review","volume":"42","author":"Vasconcelos","year":"2013","journal-title":"J\u00a0Oral Pathol Med"},{"issue":"7","key":"10.1016\/j.mayocp.2016.09.015_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","article-title":"Bone turnover markers: use in osteoporosis","volume":"8","author":"Naylor","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.015_bib32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1359\/JBMR.050104","article-title":"Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures","volume":"20","author":"Hochberg","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.mayocp.2016.09.015_bib33","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"Boonen","year":"2004","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.015_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616305912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616305912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T10:59:14Z","timestamp":1536231554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616305912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0025619616305912"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.015","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}